Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 2
1982 1
1983 3
1984 35
1985 7
1986 7
1987 5
1988 10
1989 14
1990 18
1991 20
1992 14
1993 22
1994 18
1995 22
1996 16
1997 9
1998 10
1999 14
2000 10
2001 18
2002 20
2003 23
2004 12
2005 23
2006 20
2007 24
2008 27
2009 28
2010 32
2011 40
2012 26
2013 53
2014 47
2015 40
2016 44
2017 40
2018 39
2019 45
2020 45
2021 74
2022 77
2023 70
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

1,082 results

Results by year

Filters applied: . Clear all
Page 1
Cefoperazone/sulbactam-induced hemolytic anemia.
Sun XM, Liu LH, Wu Q, Wang HG. Sun XM, et al. J Postgrad Med. 2023 Jan-Mar;69(1):46-49. doi: 10.4103/jpgm.JPGM_1335_20. J Postgrad Med. 2023. PMID: 34528516 Free PMC article.
After cefoperazone/sulbactam was given as anti-infection treatment, the patient developed hemolytic anemia on the third day. Cefoperazone/sulbactam was discontinued and replaced with meropenem. ...
After cefoperazone/sulbactam was given as anti-infection treatment, the patient developed hemolytic anemia on the third day. …
Cefoperazone sodium/sulbactam sodium vs piperacillin sodium/tazobactam sodium for treatment of respiratory tract infection in elderly patients.
Wang XX, Ma CT, Jiang YX, Ge YJ, Liu FY, Xu WG. Wang XX, et al. World J Clin Cases. 2021 Oct 16;9(29):8694-8701. doi: 10.12998/wjcc.v9.i29.8694. World J Clin Cases. 2021. PMID: 34734047 Free PMC article.
METHODS: Seventy-four elderly patients with respiratory tract infection were randomly allocated to a study (n = 37; treated with cefoperazone sodium/sulbactam sodium) or control (n = 37; treated with piperacillin sodium/tazobactam sodium …
METHODS: Seventy-four elderly patients with respiratory tract infection were randomly allocated to a study (n = 37; treated with cefopera …
Polymyxin B, Cefoperazone Sodium-Sulbactam Sodium, and Tigecycline against Multidrug-Resistant Acinetobacter baumannii Pneumonia.
Hu G, Liu W, Wang M. Hu G, et al. Evid Based Complement Alternat Med. 2022 May 31;2022:1968020. doi: 10.1155/2022/1968020. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35685727 Free PMC article. Retracted.
PURPOSE: The purpose of this study is to investigate the significance of polymyxin B in combination with cefoperazone sodium-sulbactam sodium (CSSS) and tigecycline for the treatment of multidrug-resistant Acinetobacter baumannii- (MDRAB-) induced pneu …
PURPOSE: The purpose of this study is to investigate the significance of polymyxin B in combination with cefoperazone sodium- …
Cefoperazone/sulbactam: New composites against multiresistant gram negative bacteria?
Ku YH, Yu WL. Ku YH, et al. Infect Genet Evol. 2021 Mar;88:104707. doi: 10.1016/j.meegid.2021.104707. Epub 2021 Jan 5. Infect Genet Evol. 2021. PMID: 33418147 Review.
Sulbactam, a class A beta-lactamase inhibitor, added to cefoperazone either at a fixed 8 mg/L level of sulbactam or at a level of fixed cefoperazone: sulbactam ratio (2:1) would constitute a combination form of cefoperazone/sulbactam …
Sulbactam, a class A beta-lactamase inhibitor, added to cefoperazone either at a fixed 8 mg/L level of sulbactam or at …
Model-Informed Drug Development of New Cefoperazone Sodium and Sulbactam Sodium Combination (3:1): Pharmacokinetic/Pharmacodynamic Analysis and Antibacterial Efficacy Against Enterobacteriaceae.
Ji XW, Zhu X, Li Y, Xue F, Kuan IHS, He QF, Meng XR, Xiang XQ, Cui YM, Zheng B. Ji XW, et al. Front Pharmacol. 2022 Jul 18;13:856792. doi: 10.3389/fphar.2022.856792. eCollection 2022. Front Pharmacol. 2022. PMID: 35924047 Free PMC article.
For the other tested bacteria, the above regimens achieved a similar PTA. Conclusions: Cefoperazone/sulbactam (3:1) showed similar bactericidal activity to sulperazon [cefoperazone/sulbactam (2:1)] against the tested bacteria. For the ESBL-producing an …
For the other tested bacteria, the above regimens achieved a similar PTA. Conclusions: Cefoperazone/sulbactam (3:1) showed sim …
Effect of cefoperazone sulbactam sodium combined with meropenem on the immune function in the treatment of neonatal pneumonia caused by multidrug-resistant bacteria.
Lin M, Zhu S, Weng H, Zhu Y. Lin M, et al. Am J Transl Res. 2021 Jun 15;13(6):6342-6351. eCollection 2021. Am J Transl Res. 2021. PMID: 34306373 Free PMC article.
OBJECTIVE: To explore the effect of cefoperazone sulbactam sodium combined with meropenem on the immune function in the treatment of neonatal multi-drug resistant pneumonia. ...The children were randomly divided into a combined group (n=80, combined therapy) …
OBJECTIVE: To explore the effect of cefoperazone sulbactam sodium combined with meropenem on the immune function in the …
Differential Proteomic and Genomic Comparison of Resistance Mechanism of Pseudomonas aeruginosa to Cefoperazone Sodium/Sulbactam Sodium.
Cai S, Zhang K, Wei F, Yang L, Song D, Luo J, Huang H, Gao X, DU G, Kong J, Chen Y. Cai S, et al. An Acad Bras Cienc. 2022 Sep 5;94(3):e20211160. doi: 10.1590/0001-3765202220211160. eCollection 2022. An Acad Bras Cienc. 2022. PMID: 36074406 Free article.
The aim of this study was to determine the resistance mechanism of Pseudomonas aeruginosa to cefoperazone sodium/sulbactam sodium. We retrospectively analyzed the drug resistance of P.a isolated at the First Affiliated Hospital of Guangxi Medical Unive …
The aim of this study was to determine the resistance mechanism of Pseudomonas aeruginosa to cefoperazone sodium/sulbactam …
Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder.
Miao W, Guo J, Cheng H, Zhao Q. Miao W, et al. Infect Drug Resist. 2023 Sep 21;16:6277-6284. doi: 10.2147/IDR.S429706. eCollection 2023. Infect Drug Resist. 2023. PMID: 37766881 Free PMC article.
PURPOSE: Cefoperazone/sulbactam is a beta-lactam/beta-lactamase inhibitor combination effective against intra-abdominal, urinary tract, and respiratory infections. Although some studies have suggested that cefoperazone/sulbactam is associated with coag …
PURPOSE: Cefoperazone/sulbactam is a beta-lactam/beta-lactamase inhibitor combination effective against intra-abdominal, urina …
Risk-factor analysis and predictive-model development of acute kidney injury in inpatients administered cefoperazone-sulbactam sodium and mezlocillin-sulbactam sodium: a single-center retrospective study.
Zhang R, Gao L, Chen P, Liu W, Huang X, Li X. Zhang R, et al. Front Pharmacol. 2023 Jun 8;14:1170987. doi: 10.3389/fphar.2023.1170987. eCollection 2023. Front Pharmacol. 2023. PMID: 37361226 Free PMC article.
Methods: Data from all adult inpatients who used cefoperazone-sulbactam sodium and mezlocillin-sulbactam sodium at the First Affiliated Hospital of Shandong First Medical University between January 2018 and December 2020 were analyzed retrospect …
Methods: Data from all adult inpatients who used cefoperazone-sulbactam sodium and mezlocillin-sulbactam sodi …
1,082 results